drugset
Drugs / Genetically Engineered Hematopoietic Stem Progenitor Cells
last change Feb 2024 re-read 9 days ago

Genetically Engineered Hematopoietic Stem Progenitor Cells

Cell therapy

Developed for
Fanconi anemia
Investigated by
Fred Hutchinson Cancer Center · National Heart, Lung, and Blood Institute (NHLBI) · Rocket Pharma Limited

Trials 1

today NCT01331018 · Ph 1
2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT01331018 Feb 2012 → Feb 2024 Fanconi anemia Fred Hutchinson Cancer Center Terminated No outcome recorded Stop: Business
Comparator or background therapy1 trial
Phase 2 NCT04871607 Background Nov 2021 → Oct 2029 expected Hodgkins lymphoma City of Hope Medical Center Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Genetically Engineered Hematopoietic Stem Progenitor Cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT04871607 ↗
1

NCT01331018 ↗
Action Restore “corrected in the laboratory by introduction of the normal gene” NCT01331018 ↗
Modality Cell therapy “genetically modified hematopoietic progenitor cell therapy” NCT01331018 ↗
Route Other “Given via infusion” NCT04871607 ↗